Repository logo
 

Measuring cerebral enzymatic activity, brain pH and extracranial muscle metabolism with hyperpolarized 13C-pyruvate.

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

Hyperpolarized carbon-13 (13C) magnetic resonance imaging (MRI) has shown promise for non-invasive assessment of the cerebral metabolism of [1-13C]pyruvate in both healthy volunteers and patients. The exchange of pyruvate to lactate catalysed by lactate dehydrogenase (LDH) and that of pyruvate flux to bicarbonate through pyruvate dehydrogenase (PDH) are the most widely studied reactions in vivo. Here we show the potential of the technique to probe additional enzymatic activity within the brain. Approximately 50 s after intravenous injection of hyperpolarized pyruvate, high-flip-angle pulses were used to detect cerebral 13C-labelled carbon dioxide (13CO2), in addition to the 13C-bicarbonate (H13CO3 -) subsequently formed by carbonic anhydrase (CA). Brain pH measurements, which were weighted towards the extracellular compartment, were calculated from the ratio of H13CO3 - to 13CO2 in seven volunteers using the Henderson-Hasselbalch equation, demonstrating an average pH ± SD of 7.40 ± 0.02, with inter-observer reproducibility of 0.04. In addition, hyperpolarized [1-13C]aspartate was also detected, demonstrating irreversible pyruvate carboxylation to oxaloacetate by pyruvate carboxylase (PC) and subsequent transamination by aspartate aminotransferase (AST), with the average flux being on average 11% ± 3% of that through PDH. A hyperpolarized [1-13C]alanine signal was also detected, but this was localized to extracranial muscle tissue in keeping with skeletal alanine aminotransferase (ALT) activity. The results demonstrate the potential of hyperpolarized 13C-MRI to assess cerebral and extracerebral [1-13C]pyruvate metabolism in addition to LDH and PDH activity. Non-invasive measurements of brain pH could be particularly important in assessing cerebral pathology given the wide range of disease processes that alter acid-base balance.

Description

Publication status: Published


Funder: NIHR Cambridge Biomedical Research Centre; doi: http://dx.doi.org/10.13039/501100018956


Funder: National Institute for Health and Care Research; doi: http://dx.doi.org/10.13039/501100000272


Funder: Cancer Research UK; doi: http://dx.doi.org/10.13039/501100000289


Funder: Lundbeck Foundation; doi: http://dx.doi.org/10.13039/501100003554


Funder: Multiple Sclerosis Society; doi: http://dx.doi.org/10.13039/501100000381


Funder: Cambridge Biomedical Research Centre; doi: http://dx.doi.org/10.13039/501100018956


Funder: CRUK Cambridge Centre; doi: http://dx.doi.org/10.13039/501100014679


Funder: Cambridge Experimental Cancer Medicine Centre; doi: http://dx.doi.org/10.13039/501100018956


Funder: Evelyn Trust; doi: http://dx.doi.org/10.13039/501100004282


Funder: Addenbrooke's Charitable Trust; doi: http://dx.doi.org/10.13039/501100002927


Funder: Canadian Institute for Advanced Research (CIFAR); doi: http://dx.doi.org/10.13039/100007631


Funder: Gates Cambridge Trust; doi: http://dx.doi.org/10.13039/501100005370


Funder: NIHR/Wellcome Trust Cambridge Clinical Research Facility

Journal Title

NMR Biomed

Conference Name

Journal ISSN

0952-3480
1099-1492

Volume Title

Publisher

Wiley

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Cancer Research Uk (None)
Cancer Research UK (C12912/A27150)
National Institute for Health and Care Research (IS-BRC-1215-20014)
Cancer Research UK (C19212/A29082)
Multiple Sclerosis Society (35)
Lundbeck Foundation (via Aarhus University) (L. Hanberg/J.Gaarde Kristensen)
We have funding from Cancer Research UK (CRUK; C19212/A27150; C19212/A16628), the Lundbeck Foundation, the Multiple Sclerosis Society (2015–35), the National Institute of Health Research (NIHR), Cambridge Biomedical Research center (BRC-1215–20014), CRUK Cambridge Centre, the Cambridge Experimental Cancer Medicine Centre, the Evelyn Trust, Addenbrooke's Charitable Trust, Canadian Institute for Advanced Research (CIFAR), the Gates Cambridge Trust and the NIHR/Wellcome Trust Cambridge Clinical Research Facility.